Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Elevated Levels of IgG2 Antibodies Protect Some Types of Gram-Negative Bacteria

By BiotechDaily International staff writers
Posted on 27 Aug 2014
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
ADVERTISEMENT
SARTORIUS AG
The finding that an overabundance of a certain class of antibodies protects some bacteria from the effects of antibiotics has marked implications for our understanding of the protection generated by natural infections and for the design of vaccines, which should avoid inducing such inhibitory antibodies.

Investigators at the University of Birmingham (United Kingdom) worked with patients that had bronchiectasis—a chronic infection characterized by persistent cough, shortness of breath, and chest pain—or lung infection caused by the bacterium Pseudomonas aeruginosa.

They reported in the August 2014 online edition of the Journal of Experimental Medicine that in a significant portion of these patients, antibodies protected the bacterium from complement-mediated killing. Strains that resisted antibody-induced, complement-mediated killing produced a lipopolysaccharide containing O-antigen. In particular, they found that inhibition of antibody-mediated killing was caused by excess production of O-antigen–specific antibodies of the IgG2 class. Depletion of IgG2 to O-antigen restored the ability of sera to kill strains with long-chain O-antigen.

Patients with impaired serum-mediated killing of P. aeruginosa by IgG2 were shown to have poorer respiratory function than infected patients who did not produce the inhibitory antibody.

The authors suggested that excessive binding of IgG2 to O-antigen shielded the bacterium from other antibodies that could induce complement-mediated killing. Since there is significant sharing of O-antigen structure between different Gram-negative bacteria, this IgG2-mediated impairment of killing could be operating in other Gram-negative infections as well. These findings have marked implications for understanding the nature of protection generated by natural infections and for the design of vaccines, which should avoid inducing IgG2 class inhibitory antibodies.

Related Links:

University of Birmingham 



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.